



OPEN

Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients

Toshinori Murata, Mineo Kondo, Makoto Inoue, Shintaro Nakao, Rie Osaka, Chieko Shiragami, Kenji Sogawa, Akikazu Mochizuki, Rumiko Shiraga, Yohei Ohashi, Takeumi Kaneko, Chikatapu Chandrasekhar, Akitaka Tsujikawa & Motohiro Kamei

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-020-79051-1>, published online 12 January 2021

The original version of this Article contained errors in the Discussion section.

As a result,

“While direct comparisons are not possible, owing to data being analyzed at different time points and in heterogeneous settings, the mean number of injections in the ranibizumab monotherapy arm (one + PRN regimen) of the current ZIPANGU study (4.3 injections in 12 months) was lower compared with the number of injections reported in previous multicenter clinical trials: 8.5 injections in 12 months (six + PRN regimen) in the BRAVO study³⁵ and 4.8 injections in 6 months (three + PRN regimen) in the BRIGHTER study³⁴.”

now reads:

“While direct comparisons are not possible, owing to data being analyzed at different time points and in heterogeneous settings, the mean number of injections in the ranibizumab monotherapy arm (one + PRN regimen) of the current ZIPANGU study (4.3 injections in 12 months) was lower compared with the number of injections reported in previous multicenter clinical trials: 8.4 injections in 12 months (six + PRN regimen) in the BRAVO study¹⁴ and 4.8 injections in 6 months (three + PRN regimen) in the BRIGHTER study³⁴.”

And,

“Of note, however, even the vision improvement in the combination arm (15.0 letters) of the present study was comparable to that reported in previous multicenter clinical trials of anti-VEGF monotherapy such as the BRIGHTER (15.5 letters with 14 ranibizumab injections in the three + PRN regimen²³, VIBRANT (17.1 letters with 9 aflibercept injections in the six + bimonthly regimen¹⁷, and BRAVO (18.3 letters with 8.4 ranibizumab injections in the six + PRN regimen)¹⁴ studies.

When focusing on the ranibizumab monotherapy arms, it is of particular interest to note that the ZIPANGU monotherapy arm showed a comparable or even greater improvement in vision (22 letters) compared with the BRAVO (18.3 letters)¹⁴ and BRIGHTER (15.5 letters)²³ studies, despite the fact that patients in the monotherapy arm of the ZIPANGU study (4.3 injections) received a lower number of ranibizumab injections than those in the BRAVO (8.4 injections) and BRIGHTER studies (14 injections).”

now reads:

Published online: 07 July 2021

“Of note, however, even the vision improvement in the combination arm (15.0 letters) of the present study was comparable to that reported in previous multicenter clinical trials of anti-VEGF monotherapy such as the BRIGHTER (15.5 letters with 11.4 ranibizumab injections in the three + PRN regimen²³, VIBRANT (17.1 letters with 9 aflibercept injections in the six + bimonthly regimen¹⁷, and BRAVO (18.3 letters with 8.4 ranibizumab injections in the six + PRN regimen)¹⁴ studies.

When focusing on the ranibizumab monotherapy arms, it is of particular interest to note that the ZIPANGU monotherapy arm showed a comparable or even greater improvement in vision (22 letters) compared with the BRAVO (18.3 letters)¹⁴ and BRIGHTER (15.5 letters)²³ studies, despite the fact that patients in the monotherapy arm of the ZIPANGU study (4.3 injections) received a lower number of ranibizumab injections than those in the BRAVO (8.4 injections) and BRIGHTER studies (11.4 injections).”

In addition, in the Supplementary Information file,

“Focal/grid short-pulse laser treatment was performed to suppress excess production of vascular endothelial growth factor (VEGF) by alleviating retinal ischemia. To achieve this, the entire capillary non-perfusion area in the vascular arcade was covered with focal/grid short-pulse laser treatment. OCT and fluorescein angiography were used to depict the capillary non-perfusion area; in cases where high-resolution OCT images could not be acquired due to the effects of retinal bleeding or edema, focal/grid short-pulse laser treatment of treatable lesions was performed in the area enclosed by the nasal border, the central fovea border, the peripheral border, and the temporal border.”

now reads:

“Grid short-pulse laser treatment was performed to suppress excess production of vascular endothelial growth factor (VEGF) by alleviating retinal ischemia. To achieve this, the entire capillary non-perfusion area in the vascular arcade was covered with grid short-pulse laser treatment. OCT and fluorescein angiography were used to depict the capillary non-perfusion area; in cases where high-resolution OCT images could not be acquired due to the effects of retinal bleeding or edema, grid short-pulse laser treatment of treatable lesions was performed in the area enclosed by the nasal border, the central fovea border, the peripheral border, and the temporal border.”

The original Supplementary Information file is provided below.

The original Article and its Supplementary Information file have been corrected.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-93187-8>.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021